3D molecular model of the complex formed between anti-CD19 scFv expressed from a circular RNA (Blue), and its target CD19 (Green)
Circurna is advancing a focused pipeline selected to enable early clinical validation of the platform while supporting long-term expansion into high-value therapeutic areas.
Notably shorter time to advance drug candidates into clinical trials
